Cargando…

Continuum of hepatitis C care cascade in prison and following release in the direct-acting antivirals era

BACKGROUND: People with criminal justice involvement contribute remarkably to the rising hepatitis C virus (HCV) burden; however, the continuum of care is a major barrier to prison-based programs. We aimed to evaluate a comprehensive HCV care model in an Iranian provincial prison. METHODS: Between 2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hariri, Sanam, Sharafi, Heidar, Sheikh, Mahdi, Merat, Shahin, Hashemi, Farnaz, Azimian, Fatemeh, Tamadoni, Babak, Ramazani, Rashid, Gouya, Mohammad Mehdi, Abbasi, Behzad, Tashakorian, Mehrzad, Alasvand, Ramin, Alavian, Seyed Moayed, Poustchi, Hossein, Malekzadeh, Reza
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576794/ https://www.ncbi.nlm.nih.gov/pubmed/33081794 http://dx.doi.org/10.1186/s12954-020-00431-x

Ejemplares similares

Liver Disease Burden of Hepatitis C Virus Infection in Iran and the Potential Impact of Various Treatment Strategies on the Disease Burden
por: Hajarizadeh, Behzad, et al.
Publicado: (2016)

IL28B polymorphism, Explanation for Different Responses to Therapy in Hepatitis C Patients
por: Sharafi, Heidar, et al.
Publicado: (2011)

Hepatitis C resistance to NS5A inhibitors: Is it going to be a problem?
por: Sharafi, Heidar, et al.
Publicado: (2018)

How Can We Make Decision for Patients With Chronic Hepatitis B According to Hepatitis B Virus (HBV) DNA Level?
por: Keshvari, Maryam, et al.
Publicado: (2014)

What is the ethnicity-specific impact of genetic polymorphisms on the response to hepatitis C treatment in an admixed population of Brazilian patients?
por: Keshvari, Maryam, et al.
Publicado: (2014)

Efficacy of 24-Week Pegylated Interferon Alpha and Ribavirin Combination Therapy in Highly Selected Patients Infected With Hepatitis C Virus Genotype 1
por: Sharafi, Heidar, et al.
Publicado: (2015)

Comparison of Serum Hepatitis B Virus DNA and HBsAg Levels Between HBeAg-Negative and HBeAg-Positive Chronic Hepatitis B Patients
por: Keshvari, Maryam, et al.
Publicado: (2015)

Harm reduction program and hepatitis C prevalence in people who inject drugs (PWID) in Iran: an updated systematic review and cumulative meta-analysis
por: Rajabi, Abdolhalim, et al.
Publicado: (2021)

Prevalence of Hepatitis B and C Infections and Associated Risk Factors in Pars Cohort Study, Southern Iran
por: Hariri, Sanam, et al.
Publicado: (2021)

HIV prevalence and related risk behaviours among prisoners in Iran: results of the national biobehavioural survey, 2009
por: Navadeh, Soodabeh, et al.
Publicado: (2013)

Appropriate Genotyping of Hepatitis B Virus in Iran
por: Jazayeri, Seyed Mohammad, et al.
Publicado: (2015)

Economic evaluation of pan-genotypic generic direct-acting antiviral regimens for treatment of chronic hepatitis C in Iran: a cost-effectiveness study
por: Tasavon Gholamhoseini, Mohammad, et al.
Publicado: (2022)

A simple risk-based strategy for hepatitis C virus screening among incarcerated people in a low- to middle-income setting
por: Hariri, Sanam, et al.
Publicado: (2020)

The Impact of IFNL4 rs12979860 Polymorphism on Spontaneous Clearance of Hepatitis C; A Case-Control Study
por: Sharafi, Heidar, et al.
Publicado: (2014)

Molecular Tracing of Hepatitis C Virus Genotype 1 Isolates in Iran: A NS5B Phylogenetic Analysis with Systematic Review
por: Hesamizadeh, Khashayar, et al.
Publicado: (2016)

The interferon lambda 4 rs368234815 predicts treatment response to pegylated-interferon alpha and ribavirin in hemophilic patients with chronic hepatitis C
por: Keshvari, Maryam, et al.
Publicado: (2016)

Interferon Alpha-2b Therapy in Chronic Hepatitis Delta
por: Keshvari, Maryam, et al.
Publicado: (2014)

Harm reduction during the COVID-19 outbreak in Iran
por: Karimi-Sari, Hamidreza, et al.
Publicado: (2020)

Advocacy and piloting the first needle and syringe exchange program in Iranian prisons
por: Shahbazi, Mohammad, et al.
Publicado: (2010)

Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline
por: Alavian, Seyed Moayed, et al.
Publicado: (2016)

The ITPA and C20orf194 Polymorphisms and Hematological Changes During Treatment With Pegylated-Interferon Plus Ribavirin in Patients With Chronic Hepatitis C
por: Pouryasin, Mohammad, et al.
Publicado: (2016)

Real-life efficacy of generic sofosbuvir/ledipasvir for treatment of Iranian patients with chronic hepatitis C: A cohort study
por: Sharafi, Heidar, et al.
Publicado: (2020)

Mysterious Linkages Between Hepatitis C Virus Genotypes, Interleukin-28B Genotypes and Viral Clearance- A Meta-Analysis
por: Aalaei-Andabili, Seyed Hossein, et al.
Publicado: (2014)

Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting Antivirals
por: Hesamizadeh, Khashayar, et al.
Publicado: (2016)

The Distribution of Hepatitis C Virus Genotypes in Middle Eastern Countries: A Systematic Review and Meta-Analysis
por: Ghaderi-Zefrehi, Hossein, et al.
Publicado: (2016)

Systematic Review and Meta-Analysis of Global Prevalence of HBsAg and HIV and HCV Antibodies among People Who Inject Drugs and Female Sex Workers
por: Rashti, Roya, et al.
Publicado: (2020)

Predictors of Drug Injection in High-Risk Populations of Prisoners with a History of Tattooing: A Cross-Sectional Study
por: Jafari, Saeede, et al.
Publicado: (2019)

Prevalence of Hepatitis B and Hepatitis C Infections among Incarcerated Individuals in Iran: A Cross-Sectional National Bio-behavioral Study in 2019
por: Moradi, Ghobad, et al.
Publicado: (2021)

Tattooing among Iranian prisoners: results of the two national biobehavioral surveillance surveys in 2015–2016()()
por: Jafari, Saeede, et al.
Publicado: (2020)

Upper Normal Limits of Serum Alanine Aminotransferase in Healthy Population: A Systematic Review
por: Kolahdoozan, Shadi, et al.
Publicado: (2020)

Treatment of hepatitis C virus infection with direct-acting antiviral agent-based regimens in Iranian patients with hereditary bleeding disorders
por: Sharafi, Heidar, et al.
Publicado: (2021)

Development and Validation of a Simple, Rapid and Inexpensive PCR-RFLP Method for Genotyping of Common IL28B Polymorphisms: A Useful Pharmacogenetic Tool for Prediction of Hepatitis C Treatment Response
por: Sharafi, Heidar, et al.
Publicado: (2012)

Distribution of IL28B Genotypes in Iranian Patients with Chronic Hepatitis C and Healthy Individuals
por: Sharafi, Heidar, et al.
Publicado: (2012)

Detection of Hepatitis C Virus RNA in Blood and Saliva of Transfusion-Dependent Thalassemia Patients Diagnosed with Hepatitis C
por: Hooshmand, Behzad, et al.
Publicado: (2018)

Efficacy of Prolonged Treatment With Pegylated Interferon (Peg-IFN) and Ribavirin in Thalassemic Patients With Hepatitis C Who Relapsed After Previous Peg-IFN-Based Therapy
por: Sandoughdaran, Saleh, et al.
Publicado: (2015)

Hepatitis A Virus and Hepatitis E Virus Seroprevalence Among Blood Donors in Tehran, Iran
por: Hesamizadeh, Khashayar, et al.
Publicado: (2016)

Tehran Hepatitis Conference: An International Meeting with the Goal of Middle East without Viral Hepatitis
por: Fathi, Meisam, et al.
Publicado: (2016)

Subjective Proximity to Green Spaces and Blood Pressure in Children and Adolescents: The CASPIAN-V Study
por: Abbasi, Behzad, et al.
Publicado: (2020)

Combination of sofosbuvir, pegylated-interferon and ribavirin for treatment of hepatitis C virus genotype 1 infection: a systematic review and meta-analysis
por: Dolatimehr, Fardin, et al.
Publicado: (2017)

The Impact of Illicit Drug Use on Spontaneous Hepatitis C Clearance: Experience from a Large Cohort Population Study
por: Poustchi, Hossein, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_59kh8huimvi89nqkak34js8eq4